LYDERM CREAM

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

FLUOCINONIDE

可用日期:

TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.

ATC代码:

D07AC08

INN（国际名称）:

FLUOCINONIDE

剂量:

0.05%

药物剂型:

CREAM

组成:

FLUOCINONIDE 0.05%

给药途径:

TOPICAL

每包单位数:

15/60 GM

处方类型:

Prescription

治疗领域:

ANTI-INFLAMMATORY AGENTS

產品總結:

Active ingredient group (AIG) number: 0106313001; AHFS:

授权状态:

APPROVED

授权日期:

2003-09-04

产品特点

_LYDERM Product Monograph Page 1 of 22 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
LYDERM
Fluocinonide
Ointment, Gel and Cream, USP
0.05% w/w
TOPICAL CORTICOSTEROIDS
TAROPHARMA, Date of Initial Authorization:
A DIVISION OF TARO PHARMACEUTICALS INC. December 8, 1997
130 East Drive
Brampton, Ontario, Canada
L6T 1C3 Date of Revision:
December 5, 2023
Control #: 267880
_LYDERM Product Monograph Page 2 of 22 _
TABLE OF CONTENTS
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFOR
M
ATION..........................................................4
1
INDICATIONS
..................................................................................................................4
2
CONTRAINDICATIONS
.................................................................................................4
3
DOSAGE AND ADMINISTRATION
.............................................................................4
3.1
Recommended Dose and Dosage
Adjustment
...........................................................4
4
OVERDOSAGE
.................................................................................................................4
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND
P
AC
K
A
G
ING ................5
6
WARNINGS AND PRECAUTIONS
...............................................................................6
6.1
Ge
ne
r
al
.......................................................................................................................6
6.2
Endocrine and
Metabolism
........................................................................................6
6.3
Ophthalmic.................................................................................................................6
6.4
Hepatic
.......................................................................................................................6
6.5
Immune
......................................................................